1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [amiyabarik.scb@gmail.com].
   


6. For how long will this data be available start date provided 30-09-2023 and end date provided 30-09-2028?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - Nil

After clearance from the institutional ethical committee (IEC), registering in CTRI, and obtaining written informed consent, 50 patients will be randomized into two study groups based on a computer-generated random number. The group allocation will be concealed by keeping the numbers in sealed opaque envelopes that will be opened just prior to shifting the patient to the operation room (OR).

The patient will be shifted into the OR and standard American Society of Anesthesiologists (ASA) monitoring like electrocardiogram (ECG), non-invasive blood pressure (NIBP), pulse oximetry (SPO2), and temperature will be initiated. An intravenous (IV) line will be secured and 0.9% normal saline will be infused. General anaesthesia induction will be done with an IV injection of fentanyl 2mcg/ kg and injectionpropofoL 1-2.5 mg/kg in titration till loss of verbal response. After establishing bag and mask ventilation, IVinjectionvecuronium 0.1 mg/kg will be used for muscle relaxation under the guidance of neuromuscular transmission (NMT) monitoring. Preoxygenation will be carried out for four minutes. Following the airway will be secured with either PLMA or ETI as per group allocation.

Group P: PLMA (size 3 for 30–50 kg, size 4 for 50–70 kg, and size 5 for >70 kg patients) will be used to secure the airway.

Group E: ETT (size 8.0/8.5 mm for males and size 7.0/7.5 mm for females) of appropriate size will be used to secure the airway.

Proper placement of the PLMA and ETT will be confirmed by capnography, bilateral symmetrical chest rises, and air entry on chest auscultation. No audible leaking sound, good thoracic undulation, stable pulse oxygen saturation (>95%), and capnography will be considered successful ventilation. Air leaks will be verified by auscultation at the different head positions (neutral, anterior flexion, and left and right rotation) to determine whether ventilation of PLMA is successful. If PLMA fails (more than 3 attempts) to achieve successful ventilation, then the airway will be secured with ETI. Patients in both groups will be ventilated using volume control mode and tidal volume (VT) and respiratory rate (RR) will be adjusted to maintain end-tidal carbon dioxide between 30-35 mm Hg. Maintenance of anaesthesia will be done with 50:50% oxygen:nitrous oxide with sevoflurane, intermittent vecuronium [as per train of four (TOF) count], and fentanyl as per patient requirement. In both groups, ONSDs will be measured in both eyes using an ultrasonography device in the supine position. A Tegaderm will be used to cover the closed eye so that the water-soluble gel doesn’t enter the eye. A 7.5 MHz linear ultrasound probe will be gently placed in a transverse plane over the gel. The ONSD will be measured 3 mm behind the optic disc using an electronic caliper. The ONSD measurement values will be determined for each eye by calculating the mean value of the 3 measurements. It will be measured before intubation (T0), immediately after intubation (T1), after 5 minutes (T2), and after 10 minutes (T3). The patient will be handed over to the surgeon to carry out the surgery. Following completion of the surgery, with the onset of spontaneous respiration and a TOF count of 4, the patient will be reversed with IVinjectionglycopyrrolate 10 mcg/kg and injection of neostigmine 50 mcg/kg. PLMA or ETT will be removed, once the patients become conscious and follow the command.